ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma. Georgiou M, Ntavelou P, Stokes W, Roy R, et al. Oncogene 2022 Mar 18. pii: 10.1038/s41388-022-02251.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Georgiou M, Ntavelou P, Stokes W, Roy R, et al. ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma. Oncogene 2022 Mar 18. pii: 10.1038/s41388-022-02251.
PMID: 35301407